KEGG   DRUG: Abatacept
Entry
D03203                      Drug                                   
Name
Abatacept (USAN/INN);
Abatacept (genetical recombination) (JAN);
Orencia (TN)
Product
ORENCIA (E.R. Squibb & Sons)
Sequence
MGVLLTQRTL LSLVLALLFP SMASMAMHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
TVLRQADSQV TEVCAATYMM GNELTFLDDS ICTGTSSGNQ VNLTIQGLRA MDTGLYICKV
ELMYPPPYYL GIGNGTQIYV IDPEPCPDSD QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS
LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
CSVMHEALHN HYTQKSLSLS PGK (Dimer: 146)
  Type
Peptide
Class
Anti-inflammatory
 DG01985  Disease modifying anti-rheumatic drug (DMARD)
Remark
Therapeutic category: 3999
ATC code: L04AA24
Product: D03203<JP/US>
Efficacy
Antirheumatic
  Disease
Rheumatoid arthritis [DS:H00630]
Juvenile idiopathic arthritis [DS:H01672]
Psoriatic arthritis [DS:H01507]
Acute graft versus host disease [DS:H00084]
Comment
Abatacept is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4.
Abatacept binds to CD80/86, to inhibit the CD28 costimulatory signal.
Treatment of autoimmune diseases such as rheumatoid arthritis (selective co-stimulation modulator, binds to the B7 family of molecules expressed on antigen-presenting cells (APC))
Target
CD80 [HSA:941] [KO:K05412]
CD86 [HSA:942] [KO:K05413]
  Pathway
hsa04514  Cell adhesion molecules
hsa04672  Intestinal immune network for IgA production
hsa05323  Rheumatoid arthritis
Interaction
Structure map
map07050  Antirheumatics - DMARDs and biological agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA24 Abatacept
      D03203  Abatacept (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Selective T-cell costimulation modulators
    Abatacept
     D03203  Abatacept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D03203  Abatacept (USAN/INN); Abatacept (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Anti-inflammatory
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D03203  Abatacept
Drug classes [BR:br08332]
 Antirheumatic agent
  DG01985  Disease modifying anti-rheumatic drug (DMARD)
   D03203  Abatacept
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD80
     D03203  Abatacept (USAN/INN) <JP/US>
    CD86
     D03203  Abatacept (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D03203
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D03203
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D03203
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D03203
Other DBs
CAS: 332348-12-6
PubChem: 17397357
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system